Gastrointestinal Cancer

Latest News

FDA approval
FDA Approves Zanidatamab for Pretreated HER2-Positive Biliary Tract Cancer

November 21st 2024

The FDA granted an accelerated approval to zanidatamab-hrii for previously treated, unresectable or metastatic HER2-positve biliary tract cancer.

Illustration of stomach.
Active Surveillance May Benefit Certain Patients With Small Nonfunctional Pancreatic NETs

September 5th 2024

Doctor, laptop and neck pain at night in agony, stressed or burnout by desk at the hospital. Woman medical professional suffering from painful injury, ache or inflammation working late on computer | Image Credit: © C Malambo/peopleimages.com - stock.adobe.com
Finding Balance to Potentially Address Burnout Among Oncology Nurses

August 1st 2024

Adding Tislelizumab to Chemo Enhances OS Benefit in PD-L1+ Esophageal Squamous Cell Carcinoma
Adding Tislelizumab to Chemo Enhances OS Benefit in PD-L1+ Esophageal Squamous Cell Carcinoma

July 26th 2024

FDA Grants Fast Track Status to Dendritic Cell Vaccine for Pancreatic Cancer
FDA Grants Fast Track Status to Dendritic Cell Vaccine for Pancreatic Cancer

July 23rd 2024

Video Series
Video Interviews
Podcasts
The Vitals
The Vitals
Oncology Nursing News
Are Hearing Tests Necessary For Adult Cancer Survivors?
Key Advances in Cancer Survivorship Toxicity Management
Latest CME Events & Activities

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

Register Now!

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

More News

© 2024 MJH Life Sciences

All rights reserved.